ArticleBJUI compass2026
Primary retroperitoneal lymph node dissection for clinical stage II seminoma: Comparative analysis against established paradigms using the National Cancer Data Base.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This paper aims to perform a comparative, real-world analysis of outcomes after primary retroperitoneal lymph node dissection (pRPLND) for clinical stage II (CSII) seminoma. Patients and Methods: Using the National Cancer Data Base, we identified patients with CSII germ cell tumours (GCT) between 2004 and 2022. Cox regression was used for survival analyses. Primary analysis examined overall survival (OS) for patients with CSII seminoma. A sensitivity analysis after energy-balancing weighting was performed. Secondary analysis examined salvage-chemotherapy-free survival (SFS) after pRPLND for CSII seminoma. Results: Primary analysis included 4661 patients (median follow-up 6.8 years, IQR 3.6-10.5 years). OS did not differ by primary treatment (vs. chemotherapy-HR1.34, 95% CI 0.93-1.93, Conclusion: OS after pRPLND for CSII seminoma appears comparable to alternatives. Risk of receiving salvage chemotherapy increases with clinical disease extent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.